Medicure Inc. Reports Increased Revenue and Improved EBITDA for Q2 2025

An update from Medicure ( (TSE:MPH) ) is now available.

Medicure Inc. reported financial results for the quarter ended June 30, 2025, with total net revenue increasing to $6.7 million from $5.2 million in the previous year. The company saw a rise in revenue from its Marley Drug business and increased sales of ZYPITAMAG® through both insured and pharmacy channels. Despite a net loss of $786,000, the company’s adjusted EBITDA improved significantly, reflecting operational efficiencies and strategic acquisitions of Gateway and West Olympia Pharmacies. These results underscore Medicure’s commitment to expanding its market presence and enhancing shareholder value.

The most recent analyst rating on (TSE:MPH) stock is a Hold with a C$1.00 price target. To see the full list of analyst forecasts on Medicure stock, see the TSE:MPH Stock Forecast page.

Spark’s Take on TSE:MPH Stock

According to Spark, TipRanks’ AI Analyst, TSE:MPH is a Neutral.

The overall stock score is primarily impacted by the company’s financial performance challenges, particularly in profitability and cash flow consistency. Technical indicators suggest a bearish trend, though oversold conditions could offer a rebound opportunity. Valuation concerns due to negative earnings further weigh down the score.

To see Spark’s full report on TSE:MPH stock, click here.

More about Medicure

Medicure Inc. is a pharmaceutical company focused on the development and commercialization of healthcare products primarily for the United States market. The company offers products such as AGGRASTAT® and ZYPITAMAG® and operates through subsidiaries like Marley Drug, which is licensed to ship medications across the U.S., including Washington D.C. and Puerto Rico.

Average Trading Volume: 3,699

Technical Sentiment Signal: Sell

Current Market Cap: C$10.96M

For an in-depth examination of MPH stock, go to TipRanks’ Overview page.